Chiesi inhaled pyridazine ALK5 inhibitor series

Chiesi inhaled pyridazine ALK5 inhibitor series: sourced facts only. name: "The optimized hits 20 and 23 might thus be considered promising starting points for the development of novel inhaled ALK5 inhibitors." [1] target: "The optimized hits 20 and 23 might thus be considered promising starting points for the development of novel inhaled ALK5 inhibitors." [1] developer: "Chiesi Farmaceutici S.p.A., Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy." [1] stage: "The most potent structurally novel hit compound 2A was subsequently subjected to a preliminary optimization for the inhaled delivery, applying physicochemical criteria aimed at minimizing systemic exposure to limit the risk of adverse side effects." [1] modality: "With this basis, we embarked on a program to identify novel ALK5 small-molecule inhibitors for the inhaled treatment of lung fibrosis." [1]